(P107) Vero SBRT Treatment of Moving Lung Tumors

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Overall, 40%-thresholded 18F-FDG PET contours nonsignificantly enlarge PTVs when multiphase free-breathing, inspiration, and expiration breath-hold scans are used for Vero SBRT. Whether 18F-FDG PET contours improve local control of moving lung tumors treated by Vero SBRT needs further study.

Charles A. Kunos, MD, PhD, John P. Shanahan, MS; Summa Cancer Institute

PURPOSE: Intrafraction motion management of moving lung tumors during stereotactic ablative body radiotherapy (SBRT) remains challenging. We investigated whether 40%-thresholded 2-[18F] fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET) images enhanced intrafraction tracking capabilities of the Vero SBRT platform.

MATERIALS AND METHODS: Three patients with six total moving lung tumors had gross tumor volume (GTV) contours created on free-breathing, end-inspiration, and end-expiration breath-hold computed tomography (CT) images. A thresholded 40% maximum standard uptake value 18F-FDG PET contour was generated. The four individual contours contributed to a single image-guided internal target volume (ITV). Vero SBRT treatment planning was conducted on the free-breathing CT dataset, with the ITV expanded all around by 5 mm for a final planning target volume (PTV). The prescription for each lesion was 40 Gy in four fractions of 10 Gy given every other day. Non-coplanar radiation doses were determined using a Monte Carlo algorithm. T-test statistics were calculated to compare parameter means.

RESULTS: The PTV was 23 cm3 on average (standard deviation [SD] = 18 cm3) without the 18F-FDG PET contour and 36 cm3 on average (SD = 32 cm3) with the 18F-FDG PET contour (P = .41). The lung V20 Gy was 2.6% on average (SD = 0.9%) without the 18F-FDG PET contour and 2.8% on average (SD = 0.5%) with the 18F-FDG PET contour (P = .68). Vero SBRT gimbal pan-and-tilt range of 4 cm was not exceeded by the addition of the 18F-FDG PET contour to the ITV.

CONCLUSIONS: Overall, 40%-thresholded 18F-FDG PET contours nonsignificantly enlarge PTVs when multiphase free-breathing, inspiration, and expiration breath-hold scans are used for Vero SBRT. Whether 18F-FDG PET contours improve local control of moving lung tumors treated by Vero SBRT needs further study.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content